ACTA Trial of the Year Award Winners 2021
Breakthroughs in prostate cancer screening and a ‘watch and wait’ treatment for collapsed lung share the Australian Clinical Trials Alliance 2021 Trial of the Year Award
- ProPSMA Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (ProPSMA): a prospective, randomised, multicentre study.
- Pneumothorax study A randomised controlled trial of conservative versus interventional treatment for spontaneous pneumothorax.


2021 ACTA Trial of the Year Award Finalist: PEPTIC
2021 ACTA Trial of the Year Commendation: REMAP-CAP
2021 Excellence in Trials Statistics Award Winner: PEPTIC
2021 Excellence in Trials Statistics Commendation: REMAP-CAP
2021 Consumer Involvement Commendation
CHIRI
'Industry Partnership Award'
.